Repurposing metformin for cancer treatment: Current clinical studies

Oncotarget

Volumn 7, Issue 26, 2016, Pages 40767-40780

  Chae, Young Kwang ^a,b   Arya, Ayush ^b   Malecek, Mary Kate ^b   Shin, Daniel Sanghoon ^c   Carneiro, Benedito ^a,b   Chandra, Sunandana ^a,b   Kaplan, Jason ^a,b   Kalyan, Aparna ^a,b   Altman, Jessica K ^a,b   Platanias, Leonidas ^a,b,d   Giles, Francis ^a,b  

^a Northwestern Medicine Developmental Therapeutics Institute ^*  (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Cancer; Clinical trials; Metformin

Indexed keywords

ADENYLATE KINASE; INSULIN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; SOMATOMEDIN C; TUBERIN; ANTINEOPLASTIC AGENT; KI 67 ANTIGEN;

ACUTE MYELOBLASTIC LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; DRUG EFFECT; DRUG MECHANISM; ENDOMETRIUM CANCER; EPIDEMIOLOGICAL DATA; GLIOBLASTOMA; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; LYMPHOMA; MELANOMA; METASTASIS; NEUROENDOCRINE TUMOR; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLID TUMOR; SQUAMOUS CELL CARCINOMA; ANIMAL; BREAST TUMOR; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DRUG EFFECTS; ENDOMETRIUM TUMOR; FEMALE; INSULIN RESISTANCE; LUNG TUMOR; METABOLISM; NEOPLASM; RISK; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INSULIN RESISTANCE; KI-67 ANTIGEN; LUNG NEOPLASMS; METFORMIN; NEOPLASMS; RISK; TREATMENT OUTCOME;

EID: 84982074226     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8194     Document Type: Article

References (57)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R and Matthews DR. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38:140-149.
2. Grzybowska M, Bober J and Olszewska M. [Metformin -mechanisms of action and use for the treatment of type 2 diabetes mellitus]. Postepy Hig Med Dosw. 2011; 65:277-285.
3. Matthaei S and Greten H. Evidence that metformin ameliorates cellular insulin-resistance by potentiating insulin-induced translocation of glucose transporters to the plasma membrane. Diabete Metab. 1991; 17:150-158.
4. Diabetes Prevention Program Research G. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012; 35:731-737.
5. Dowling RJ, Zakikhani M, Fantus IG, Pollak M and Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007; 67:10804-10812.
6. Mohammed A, Janakiram NB, Brewer M, Ritchie RL, Marya A, Lightfoot S, Steele VE and Rao CV. Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling. Transl Oncol. 2013; 6:649-659.
7. Yoshida S, Hong S, Suzuki T, Nada S, Mannan AM, Wang J, Okada M, Guan KL and Inoki K. Redox regulates mammalian target of rapamycin complex 1 (mTORC1) activity by modulating the TSC1/TSC2-Rheb GTPase pathway. J Biol Chem. 2011; 286:32651-32660.
8. Inoki K, Zhu T and Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003; 115:577-590.
9. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE and Shaw RJ. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008; 30:214-226.
10. Zakikhani M, Blouin MJ, Piura E and Pollak MN. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat. 2010; 123:271-279.
11. Vazquez-Martin A, Oliveras-Ferraros C and Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle. 2009; 8:88-96.
12. Green AS, Chapuis N, Maciel TT, Willems L, Lambert M, Arnoult C, Boyer O, Bardet V, Park S, Foretz M, Viollet B, Ifrah N, Dreyfus F, et al. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood. 2010; 116:4262-4273.
13. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD and Dennis PA. Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prev Res (Phila). 2010; 3:1066-1076.
14. Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, Tanti JF, Giorgetti-Peraldi S and Bost F. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011; 71:4366-4372.
15. Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, Marette A, Kozma SC and Thomas G. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010; 11:390-401.
16. Alfarouk KO, Verduzco D, Rauch C, Muddathir AK, Adil H, Elhassan GO and Ibrahim ME. Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question. Oncoscience. 2014; 1:777-802. doi: 10.18632/oncoscience.109.
17. Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B and Menendez JA. Metformin: multi-faceted protection against cancer. Oncotarget. 2011; 2:896-917. doi: 10.18632/ oncotarget.387.
18. Zhou X, Chen J, Yi G, Deng M, Liu H, Liang M, Shi B, Fu X, Chen Y and Chen L. Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in hepatocellular carcinoma. Oncotarget. 2016; 7:873-84. doi: 10.18632/oncotarget.6418.
19. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B and Thompson CB. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007; 67:6745-6752.
20. Shank JJ, Yang K, Ghannam J, Cabrera L, Johnston CJ, Reynolds RK and Buckanovich RJ. Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol. 2012; 127:390-397.
21. Sato A, Sunayama J, Okada M, Watanabe E, Seino S, Shibuya K, Suzuki K, Narita Y, Shibui S, Kayama T and Kitanaka C. Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK. Stem Cells Transl Med. 2012; 1:811-824.
22. Song CW, Lee H, Dings RP, Williams B, Powers J, Santos TD, Choi BH and Park HJ. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep. 2012; 2:362.
23. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA and Bae-Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecol Oncol. 2010; 116:92-98.
24. Storozhuk Y, Hopmans SN, Sanli T, Barron C, Tsiani E, Cutz JC, Pond G, Wright J, Singh G and Tsakiridis T. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer. 2013; 108:2021-2032.
25. Martin MJ, Hayward R, Viros A and Marais R. Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov. 2012; 2:344-355.
26. Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E and Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A. 2015; 112:1809-1814.
27. Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, Jones RG and Choi Y. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature. 2009; 460(7251):4-107.
28. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD and Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009; 32:1620-1625.
29. Zhang P, Li H, Tan X, Chen L and Wang S. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol. 2013; 37:207-218.
30. Wang L, Song Y, Wu GN and Yuan DM. Association of the metformin with the risk of lung cancer: a meta-analysis. Transl Lung Cancer Res. 2013; 2:259-263.
31. Deng D, Yang Y, Tang X, Skrip L, Qiu J, Wang Y and Zhang F. Association between metformin therapy and incidence, recurrence and mortality of prostate cancer: evidence from a meta-analysis. Diabetes Metab Res Rev. 2015; 31:595-602. doi: 10.1002/dmrr.2645.
32. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F and Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One. 2013; 8:e71583.
33. Wu L, Zhu J, Prokop LJ and Hassan Murad M. Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies. Sci Rep. 2015; 5:10147.
34. Bo S, Ciccone G, Rosato R, Villois P, Appendino G, Ghigo E and Grassi G. Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients. Diabetes Obes Metab. 2012; 14:23-29.
35. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA and Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care. 2012; 35:299-304.
36. Zhang ZJ and Li S. The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014; 16:707-710.
37. Niraula S, Dowling RJ, Ennis M, Chang MC, Done SJ, Hood N, Escallon J, Leong WL, McCready DR, Reedijk M, Stambolic V and Goodwin PJ. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat. 2012; 135:821-830.
38. Wallace TM and Matthews DR. The assessment of insulin resistance in man. Diabet Med. 2002; 19:527-534.
39. Hadad SM, Coates P, Jordan LB, Dowling RJ, Chang MC, Done SJ, Purdie CA, Goodwin PJ, Stambolic V, Moulder-Thompson S and Thompson AM. Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial. Breast Cancer Res Treat. 2015; 150:149-155.
40. Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, Gennari A, Trabacca MS, Galimberti V, Veronesi P, Johansson H, Aristarco V, Bassi F, et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol. 2012; 30:2593-2600.
41. Kalinsky K, Crew KD, Refice S, Xiao T, Wang A, Feldman SM, Taback B, Ahmad A, Cremers S, Hibshoosh H, Maurer M and Hershman DL. Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Cancer Invest. 2014; 32:150-157.
42. Cazzaniga M, DeCensi A, Pruneri G, Puntoni M, Bottiglieri L, Varricchio C, Guerrieri-Gonzaga A, Gentilini OD, Pagani G, Dell'Orto P, Lazzeroni M, Serrano D, Viale G and Bonanni B. The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer. 2013; 109:2792-2797.
43. Schuler KM, Rambally BS, DiFurio MJ, Sampey BP, Gehrig PA, Makowski L and Bae-Jump VL. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Med. 2015; 4:161-173.
44. Laskov I, Drudi L, Beauchamp MC, Yasmeen A, Ferenczy A, Pollak M and Gotlieb WH. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecol Oncol. 2014; 134:607-614.
45. Mitsuhashi A, Kiyokawa T, Sato Y and Shozu M. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. Cancer. 2014; 120:2986-2995.
46. De Celis Ferrari ACR, Pfiffer TEF, Alex AK, Nebuloni DR, Carneiro AQ, Capareli FC, Leite LAS, Braghiroli MIFM, Lobo J, Hoff PM and Riechelmann RP. Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas. ASCO Meeting Abstracts. 2014; 32:e15196.
47. Wilmink J, Kordes S, Zwinderman K, Mathot R, Punt CJA and Richel D. A phase II randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib, and metformin in patients with locally advanced or metastatic pancreatic cancer. ASCO Meeting Abstracts. 2014; 32:4021.
48. Joshua AM, Zannella VE, Downes MR, Bowes B, Hersey K, Koritzinsky M, Schwab M, Hofmann U, Evans A, van der Kwast T, Trachtenberg J, Finelli A, Fleshner N, Sweet J and Pollak M. A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer Prostatic Dis. 2014; 17:252-258.
49. Kritharis A, Caplain J, Rajagopal S, Grimm E, Tsichlis PN, Martell R and Saif WM. A phase I study of metformin and chemotherapy in solid tumors. ASCO Meeting Abstracts. 2014; 32:2560.
50. MacKenzie MJ, Ernst S, Johnson C and Winquist E. A phase I study of temsirolimus and metformin in advanced solid tumours. Invest New Drugs. 2012; 30:647-652.
51. Barbee MS, Ogunniyi A, Horvat TZ and Dang TO. Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology. The Annals of pharmacotherapy. 2015.
52. Pembrolizumab shows potential in breast cancer. Cancer Discov. 2015; 5:3-101.
53. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England journal of medicine. 2015; 373:23-34.
54. Groop L. Pathogenesis of type 2 diabetes: the relative contribution of insulin resistance and impaired insulin secretion. Int J Clin Pract Suppl. 2000;: 3-13.
55. Moutschen MP, Scheen AJ and Lefebvre PJ. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabete Metab. 1992; 18:187-201.
56. Moutschen M. [Alterations in natural immunity and risk of infection in patients with diabetes mellitus]. Rev Med Liege. 2005; 60(5-6):541-544.
57. Hadrup S, Donia M and Thor Straten P. Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenviron. 2013; 6:123-133.